Categories: News

Invitation to presentation of RaySearch’s interim report for the third quarter of 2024

STOCKHOLM, Oct. 21, 2024 /PRNewswire/ — Analysts, investors, and the media are invited to a presentation of RaySearch’s interim report for the third quarter of 2024 on November 8, 2024, at 10.00 am CET. The report will be published on November 8, 2024, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan Löf, founder and CEO, and Annika Blondeau Henriksson, interim CFO, will present the company’s development in a webcast. After the presentation (held in English) there is the opportunity to ask questions.

Link to webcast: RaySearch Q3, 2024

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/invitation-to-presentation-of-raysearch-s-interim-report-for-the-third-quarter-of-2024,c4053756

The following files are available for download:

https://mb.cision.com/Main/1102/4053756/3063388.pdf

RaySearch Press Release October 21, 2024

 

View original content:https://www.prnewswire.com/news-releases/invitation-to-presentation-of-raysearchs-interim-report-for-the-third-quarter-of-2024-302281487.html

SOURCE RaySearch Laboratories

Staff

Recent Posts

Med-X to Showcase a Newly Developed Nature-Cide Rat & Mouse Control Product at PestWorld 2024 in Denver Colorado from October 22-25

Management to Showcase New Nature-Cide Rat and Mouse Repellent Pouches Alongside Broader Nature-Cide Product Portfolio…

2 hours ago

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or…

2 hours ago

Optimi Health Announces Leadership Transition

Vancouver, British Columbia--(Newsfile Corp. - October 21, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX:…

3 hours ago

Base Molecular Resonance™ Technologies Receives $1.8 Billion U.S. IP Licensing Valuation in its Security Business Sector

Report Cites Projections of an Additional $3.5 Billion Upon Global Expansion STUART, Fla., Oct. 21,…

5 hours ago